AD_____

Award Number: DAMD17-03-1-0283

TITLE: Characterization of Antibody Specific for Disease
Associated Prion Protein

PRINCIPAL INVESTIGATOR: Shu G. Chen, Ph.D.

CONTRACTING ORGANIZATION: Case Western Reserve University
Cleveland, Ohio   44106

REPORT DATE: July 2004

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland   21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are
those of the author(s) and should not be construed as an official
Department of the Army position, policy or decision unless so
designated by other documentation.

20050516 050

REPORT DOCUMENTATION PAGE

1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE July 2004	3. REPORT TYPE AND DATES COVERED Annual (25 Jun 03 – 24 Jun 04)

4. TITLE AND SUBTITLE
Characterization of Antibody Specific for Disease Associated Prion Protein

5. FUNDING NUMBERS
DAMD17-03-1-0283

6. AUTHOR(S)
Shu G. Chen, Ph.D.

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)
Case Western Reserve University
Cleveland, Ohio 44106

E-Mail: shu.chen@case.edu

8. PERFORMING ORGANIZATION REPORT NUMBER

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)
U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

10. SPONSORING / MONITORING AGENCY REPORT NUMBER

11. SUPPLEMENTARY NOTES

12a. DISTRIBUTION / AVAILABILITY STATEMENT
Approved for Public Release; Distribution Unlimited

12b. DISTRIBUTION CODE

13. ABSTRACT (Maximum 200 Words)

Prion diseases are characterized by the presence of the abnormal scrapie isoform of prion protein (PrP^{Sc}) in affected brains. A conformational change is believed to convert the normal cellular prion protein (PrP^C) into PrP^{Sc}. Detection of PrP^{Sc} for diagnosis and prophylaxis is impaired because available antibodies recognizing epitopes on PrP fail to distinguish between PrP^{Sc} and PrP^C. We have discovered a novel antibody OCD4 that may overcome the above deficiency. The objective in year 1 is to characterize the specificity and selectivity of OCD4. We have accomplished this objective for year 1. The major findings and work in progress are summarized here. We have found that OCD4 is an anti-DNA antibody OCD4 that capture PrP from brains affected by prion diseases in both humans and animals but not from unaffected controls. OCD4 appears to immunoreact with DNA (or a DNA-associated molecule) that forms a conformation-dependent complex with PrP in prion diseases. We have also found that g5p, a well-established DNA-binding protein, can be used for recognizing PrP^{Sc}. Therefore, OCD4 and g5p specifically target disease-associated DNA-PrP complexes in prion diseases. Our finding opens new avenues in the study and diagnosis of prion diseases.

14. SUBJECT TERMS
Prion diseases; prion protein; Creutzfeldt-Jakob disease; prion diagnosis

15. NUMBER OF PAGES
16

16. PRICE CODE

| 17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited

Table of Contents

INTRODUCTION:

Specific capture and detection of PrP^{Sc} is critically important for prion diagnosis and prophylaxis. The purpose of our research is to characterize novel antibodies and reagents for disease-associated PrP. Specifically, the research will mainly focus on a novel antibody OCD4 for PrP^{Sc} detection. For year 1, our task is to characterize the specificity and selectivity of OCD4 including a) evaluation of the ability of OCD4 mAb in recognizing PrP from brains of all subtypes of human and animal prion diseases, and b) evaluation of the selectivity of OCD4 mAb by analyzing not only cases of healthy individuals but also cases of other non-prion neurologic disorders such as Alzheimer's disease. In addition, we also accomplished partial objective of Task 2 that is to characterize the epitope of the OCD4 monoclonal antibody (year 2).

BODY:

This research progress summarizes the work accomplished during year 1. There is only one task for year 1 (Task 1) in the approved Statement of Work. The Task 1 is to characterize the specificity and selectivity of OCD4. We have accomplished this task promptly. In addition, we have continued our research into some areas of Task 2. Our main research findings have been published recently (Zou W, Zheng J, Gray D, Gambetti P, Chen SG. Antibody to DNA detects scrapie but not normal prion protein. *Proc. Natl. Acad. Sci. USA* **101**:1380-1385, 2004). A reprint of this research article is attached in APPENDICES. The following is the description of the research findings/accomplishments associated with the Task 1 and part of the Task 2 in the approved Statement of Work.

Part 1: Research on Task 1

OCD4 specifically captures PrP^{Sc} but not PrP^{C}. We performed the immunocapture assay of PrP using the anti-DNA antibody-conjugated magnetic beads, followed by immunoblotting with an anti-PrP antibody. Immunocapture by the mAb to DNA OCD4 yielded abundant PrP from brain homogenates of CJD subjects, while no PrP was recovered from control brains free of neurological disease as well as brains with other neurodegenerative diseases such as Alzheimer's disease (Fig. 1A and data not shown). None of the other mAbs recognizing PrP sequences demonstrated such high specificity. Under the same experimental conditions, two of these antibodies to PrP widely used in current research on prion diseases, mAbs 3F4 and 6H4, immunocaptured PrP from both diseased and normal brains. 3F4 and 6H4 actually showed higher affinity for PrP^{C} than for the PrP associated with CJD brains (Fig. 1A). To exclude the possibility that

Figure 1. Immunocapture of disease-associated PrP by anti-DNA mAb OCD4. (*A*) PrP captured from brain homogenates (BH) by various mAbs. Ten µl of 10% (w/v) BH from a subject with sporadic CJD or a non-CJD control was incubated in 1ml of lysis buffer for 3 h at room temperature with OCD4, 3F4, and 6H4 that were conjugated to magnetic beads (23). After washing with a solution of 2% Tween-20 and 2% NP-40 in PBS, the samples recovered by the antibody conjugated beads were subjected to SDS-PAGE. PrP was detected by immunoblotting with 3F4. (*B*) Immunocapture of PrP from a subject with sCJD by anti-tubulin antibody and OCD4. Experimental procedures were the same as described in (A). Molecular weight markers (in kDa) are indicated on the left.

4

binding of PrP^{Sc} to OCD4-conjugated beads is non-specific, we conjugated an antibody against tubulin to the beads and assayed for PrP in CJD brain homogenate following immunocapture. No PrP was captured by this irrelevant antibody whereas abundant amounts of PrP were recovered by OCD4 from the same preparation (Fig. 1B).

OCD4 immunoreacts with DNA and OCD4 detection of PrP is competed by input DNA. To determine whether DNA is indeed the antigen recognized by OCD4, we performed the DNA dot blot assay. We found that OCD4 immunoreacts with purified DNA preparations and that the reaction is sensitive to nuclease (Fig. 2A). We also pre-absorbed the OCD4-conjugated beads with purified DNA before performing the immunocapture assay. Alternatively, we treated the brain homogenates with nuclease (Benzonase) followed by immunocapture with OCD4. No PrP was immunocaptured by OCD4 in the presence of the added DNA. However, pretreatment of the homogenate with nuclease had no effect on PrP immunocapture by OCD4, even although in a control experiment, the amount of nuclease used was sufficient to digest the DNA added to the preparation (Fig. 2B and 2C). Taken together, these findings argue that the OCD4 antigen is DNA, or a DNA-related molecule that is part of a molecular complex with disease-associated PrP^{Sc}. The ineffectiveness of the nuclease digestion suggests that the DNA present in the DNA- PrP^{Sc} complex may be protected from, or inaccessible to, nuclease digestion while maintaining the capacity to bind OCD4. Nucleic acid specifically isolated from CJD brain has been shown by others to resist nuclease treatment. Furthermore, we also observed that disease-associated PrP^{Sc} could be specifically isolated with other mAbs raised with different DNA preparations (data not shown). Alternatively, OCD4 and other mAbs to DNA as well, might recognize a conformation shared by PrP^{Sc} and DNA.

Figure 2. Immunoreactivity of OCD4 toward DNA as well as effect of DNA and nuclease on PrP capture by OCD4. (*A*) Dot blot of DNA probed with OCD4. *Right panel*: Dot blot containing indicated amounts of purified salmon DNA was incubated with HRP-conjugated OCD4. *Left panel*: Salmon sperm DNA was treated with or without nuclease (Nucl., benzonase) at 20 U/ml at 37°C for 1 h prior to dot blot with HRP-conjugated OCD4. Immunoreactivity was visualized by enhanced chemiluminescence. (*B*) Immunocapture of PrP by OCD4 following incubation with nuclease and salmon DNA. Scrapie-infected hamster BH (2 µl each) was either untreated (*control*) or treated with benzonase (*nuclease*) at 100 U/ml, followed by incubation with OCD4 conjugated beads. In a separate sample, purified salmon DNA (5 ug/ml) was pre-incubated with the OCD4-conjugated beads at 37 °C for 1 h prior to the immunocapture assay (*DNA*). PrP was detected by immunoblotting with 3F4. Molecular size is indicated on the left (in kDa). (*C*) Enzymatic digestion of DNA by nuclease. Salmon DNA (5 µg/ml) was treated with benzonase at 20 U/ml or 2 U/ml at 37°C for 1 h, or left untreated. The samples were subjected to 1.0% agarose gel electrophoresis, with a 1 kb DNA ladder (Sigma) run in parallel as DNA size standard.

The DNA binding protein g5p also captures PrP^{Sc} in a DNA-dependent manner. The DNA binding protein, g5p, encoded by the filamentous bacteriophage Ff and purified from *E. coli.*, was conjugated to magnetic beads. The g5p-conjugated beads were then

5

incubated with brain homogenates from vCJD, sCJD or normal controls. Like OCD4, g5p precipitated PrP from vCJD and sCJD brains but not from normal control brains (Fig. 3A). Moreover, the amount of the PrP captured by both g5p and OCD4 decreased in a concentration-dependent manner following the addition of DNA (Fig. 3B), further arguing that the capture of PrP by OCD4 and g5p is mediated by, or can be competed with, nucleic acid.

Figure 3. Capture of PrP from sCJD, vCJD, and normal control brains by g5p. (A) BH from subjects affected by vCJD and sCJD and from a control subject was incubated with g5p- or OCD4-conjugated beads, followed by immunoblotting with 3F4. (B) The g5p- or OCD4-conjugated beads were pre-incubated with indicated amounts of salmon DNA, followed by incubation with BH of sCJD and Immunoblotting with

OCD4 captured PrP^{Sc} is PK-resistant and OCD4 detects PrP^{Sc} of different prion strains in both humans and animals. A major portion of the PrP captured by OCD4 is resistant to PK digestion, the biochemical hallmark of PrP^{Sc} (Fig. 4A). Furthermore, while the currently available mAbs to PrP are species-sensitive because their specificity is derived from a particular PrP sequence, OCD4 captured all disease-associated PrP^{Sc} of different prion strains, which were obtained from various forms of human prion diseases, including sporadic and familial CJD, GSS, and vCJD, as well as naturally occurring and experimentally transmitted animal diseases (Fig. 4A and 4B). These


Figure 4. OCD4 captures disease-associated PrP^{Sc} from various prion-infected human and animal brains. (A) Immunocapture of PrP by OCD4 from various human prion diseases. BH (10 µl each) from subjects affected by sporadic CJD (sCJD) associated with PrP^{Sc} type 1 or PrP^{Sc} type 2 (28, 29), familial CJD linked to the E200K mutation (fCJD), and vCJD, as well as from a non-CJD control, was incubated with OCD4-conjugated beads. The bound materials were either untreated (PK-) or treated with PK (PK+) at 50 µg/ml at 37°C for 1 h. PrP was detected by immunoblotting with 3F4. (B) Immunocapture of PrP by OCD4 from various animal species. BH (2 µl each) from normal animals and those affected by BSE (cattle), scrapie (sheep), and CWD (elk), as well as experimental scrapie adapted in hamster (263K prion strain) and mouse (ME7 prion strain), was subjected to immunocapture by OCD4 as described in A. Captured PrP was detected by immunoblotting with 6H4

findings further argue that under non-denaturing conditions OCD4 captures disease-associated PrP^{Sc}, but not PrP^{C}. Furthermore, OCD4 must immunoreact with an antigen

that is bound to, but distinct from, PrP since the OCD4 capture of PrP is independent of PrP amino acid sequence.

Part 1: Research on Task 2

OCD4 captures all PK-resistant PrP fragments associated with various human prion diseases. To gain insight into the PrP bound to the putative DNA-containing complex, we took advantage of the different size of the PK-resistant PrP^{Sc} core fragments present in various prion diseases. Immunocapture of PrP by OCD4 was not affected by pre-treatment of homogenates from diseased brains with PK (Fig. 5A-C). Furthermore, all major PK-resistant fragments of PrP^{Sc} were recovered, including the 21 and19 kDa core fragment in CJD (PrP^{Sc} type 1 and 2) (Fig. 5A) spanning residues 82/97 to 231 (28, 29), which accounts for nearly two thirds of the 23-231 PrP molecule; an internal 7-8 kDa fragment in GSS (Fig. 5C) including residues 74/90 to146/153, and the C-terminal 12-13 kDa fragment in CJD (Fig. 5B) extending from residues 154/162 to 231. The co-capture by OCD4 of all major PrP^{Sc} fragments generated by PK-treatment regardless of size argues that most (if not all) of the PK-resistant region of PrP^{Sc} is stably bound to the DNA containing complex and remains with the complex after PK-treatment. It also further supports the contention that OCD4 is unlikely to react directly with PrP in the complex since the 7-8 kDa internal fragment and the 12-13 kDa C-terminal fragment share no consensus in sequence yet they are both efficiently captured by OCD4.

Figure 5. Immunocapture of various PK-resistant PrP fragments by OCD4. BH from subjects affected by sporadic CJD associated with codon 129 MM and type 2 PrP^{Sc} (sCJD MM2, *A*), familial CJD with the E200K mutation (fCJD E200K, *B*), and GSS with the P102L mutation (GSS P102L, *C*) was treated with or without PK at 50 μg/ml 37°C for 1 h. PrP was captured by the OCD4-conjugated beads and was then detected by immunoblotting with either 3F4 recognizing PrP residues 109-112 (*A*, *C*), or the anti-C antibody against human PrP residues 220-231 (*B*). Three groups of PK-resistant PrP fragments were efficiently captured by OCD4 (with their position on the blots indicated), including the ~19 kDa PrP core fragment spanning residues 97/103 to 231 (bracket,]), the internal 7/8 kDa fragment spanning residues 74/90 to 146/153 (dagger, †) and the C-terminal 12/13 kDa fragment spanning residues 154/162 to 231 (asterisk, *).

The immunocapture of PrP^{Sc} by OCD4 is conformation-dependent. Since the protease-resistance and other physicochemical features of PrP^{Sc} are thought to be dependent on protein conformation, distinct conformers of PrP^{Sc} have been characterized based on the extent of the loss in protease-resistance as a function of increased exposure to denaturants. We applied such a conformation-dependent immunoassay to compare the conformational characteristics of the PrP captured by OCD4 with those of native PrP^{Sc} present in the homogenate from the same CJD brain. The decrease of PK-resistance with rising concentrations of guanidine hydrochloride (GdnHCl) took place at a comparable rate for native PrP^{Sc} and OCD4 captured PrP (Fig. 6A and 6B), suggesting that PK-resistant forms of native PrP^{Sc} and OCD4 captured PrP have comparable conformational properties. We then examined the affinity of OCD4 for PrP as a function of GdnHCl treatment. Decreasing amounts of PrP were recovered by immunocapture with OCD4 following protein denaturation by increasing concentrations of GdnHCl (Fig. 6C), arguing that the affinity of OCD4 for PrP

is also conformation-dependent. Furthermore, by comparing panel B and C of Figure 6, it is obvious that the total PrP captured by OCD4 exceeds that in the PK-resistant fraction. Densitometry showed that over 20% of PrP was still detectable following treatment with 2.4 M GdnHCl that renders virtually all PrP^{Sc} sensitive to PK (Fig. 6C), suggesting that at least 20% of PrP recovered by OCD4 is PK-sensitive. Therefore, PrP captured by OCD4 comprises both PK-resistant and PK-sensitive PrP species as has been reported for PrP^{Sc} following a conformation-dependent assay and other analyses. Taken together, the similarity in gel migration pattern and in the conformation dependence of the PK-resistance, as well as the presence of both PK-sensitive and PK-resistant components, argue that PrP captured by OCD4 and native PrP^{Sc} are the same.

Figure 6. Conformation-dependent immunocapture of disease-associated PrP by OCD4. (*A*) PK-resistance of PrP^{Sc} as a function of GdnHCl concentrations. BH from CJD was treated with various concentrations of GdnHCl. The GdnHCl treated samples were digested with 50 µg/ml PK for 1 h at 37 °C (PK+), followed by immunoblotting with 3F4. (*B*) PK-resistance of PrP captured by OCD4 as a function of GdnHCl concentrations. The GdnHCl treated BH of CJD was subjected to immunoprecipitation with OCD4, followed by digestion with PK (IP/+PK). PrP was then detected by immunoblotting with 3F4. (*C*) Capture of PrP by OCD4 as a function of GdnHCl concentrations. The GdnHCl treated BH of CJD was subjected to immunoprecipitation with OCD4 without the PK-treatment (IP/-PK). PrP was detected by immunoblotting with 3F4. (*D*) Comparison of GdnHCl dependent loss of PrP in BH of CJD following PK digestion (solid circle), immunoprecipitation with OCD4 followed by PK digestion (empty circle), and immunoprecipitation with OCD4 without PK digestion (solid square). Intensity of PrP bands on immunoblots was quantified by densitometry, and the ratio of PrP in the GdnHCl-treated and untreated samples was plotted as a function of GdnHCl concentrations. Similar results were obtained in two additional experiments.

KEY RESEARCH ACCOMPLISHMENTS:

- We have demonstrated that OCD4 specifically captures rated that PrP^{Sc} but not PrP^{C} (Task 1a).
- We have demonstrated that OCD4 detects PrP^{Sc} of different prion strains in both humans and animals (Task 1a)..
- We have demonstrated that OCD4 recognition of PrP^{Sc} is selective since negative results are obtained in Alzheimer's disease (Task 1b).
- We have shown that OCD4 recognizes disease–associated DNA-PrP^{Sc} complexes (Task 2a).
- We have demonstrated that the ability of OCD4 in capturing PrP^{Sc} is conformation-dependent (Task 2b).

8

REPORTABLE OUTCOMES:

Publication in peer-reviewed journal:

Zou W, Zheng J, Gray D, Gambetti P, Chen SG. Antibody to DNA detects scrapie but not normal prion protein. *Proc. Natl. Acad. Sci. USA* **101**:1380-1385, 2004.

Abstracts and Presentations:

Zou W, Zheng Z, Gambetti P, Chen SG. Antibody to DNA detects scrapie but not normal prion protein. *Annual Meeting of Society for Neuroscience,* New Orleans, LA, 2003.

Takemura K, Wang P, Chen SG, Kanthasamy A, Sreevatsan S. PrP-binding characteristics of aptamers derived from DNA sequences that were co-purified with PrPSc-specific anti-nuclear monoclonal antibody. Animal Prion Diseases and The Americas, Ames, Iowa, Oct. 14-16, 2004.

Hatcher K, Zheng J, Chen SG. Cryptic peptides of the Kringle domains preferentially bind to disease-associated prion protein. *Annual Meeting of Society for Neuroscience.* Oct. 22-28, 2004.

Xie Z, Ma L, Zou W, Petersen RB, Wang W, O'Rourke KI, Jenny AL, Langenberg J, Belay ED, Schonberger LB, Kong Q, Gambetti P, Chen SG. Comparative analysis of prion protein in chronic wasting disease and in Creutzfeldt-Jakob disease. *Annual Meeting of Society for Neuroscience.* Oct. 22-28, 2004.

CONCLUSIONS:

Our research has demonstrated that OCD4, as well as g5p, a well-established DNA-binding protein, capture PrP from brains affected by prion diseases in both humans and animals but not from unaffected controls. OCD4 appears to immunoreact with DNA (or a DNA-associated molecule) that forms a conformation-dependent complex with PrP in prion diseases. While PrP immunocaptured by OCD4 is largely protease-resistant, a fraction of it remains protease-sensitive. Moreover, OCD4 detects disease-associated PrP over ten times more efficiently than a widely used antibody to PrP. Our finding that anti-DNA antibodies and g5p specifically target disease-associated DNA-PrP complexes in a wide variety of species and disease phenotypes opens new avenues in the study and diagnosis of prion diseases. The above work has been recently published (Zou et al., 2004).

The mAb OCD4 is remarkable in several respects. First, it captures the abnormal PrP associated with prion diseases with a high level of specificity and affinity while not recognizing PrP^C at all. Second, it detects both protease-sensitive and protease-resistant species of prion disease-associated PrP. Third, it suggests for the first time that both species of abnormal PrP form a complex which includes DNA or DNA-related molecules. Fourth, since several other antibodies to DNA preparations also capture the disease-associated PrP and they are easy to produce, OCD4 is likely to be the first of many novel prion-specific reagents. The knowledge gained from our research on OCD4

9

may lead to development of new strategies for the study, detection and treatment of prion diseases.

REFERENCES:

Zou W, Zheng J, Gray D, Gambetti P, Chen SG. Antibody to DNA detects scrapie but not normal prion protein. *Proc. Natl. Acad. Sci. USA* **101**:1380-1385, 2004.

APPENDICES/MANUSCRIPTS/REPRINTS:

A reprint of our published paper is attached as APPENDIX (Zou W, Zheng J, Gray D, Gambetti P, Chen SG. Antibody to DNA detects scrapie but not normal prion protein. *Proc. Natl. Acad. Sci. USA* **101**:1380-1385, 2004).

Antibody to DNA detects scrapie but not normal prion protein

Wen-Quan Zou*[†], Jian Zheng[†‡], Donald M. Gray[§], Pierluigi Gambetti*[¶], and Shu G. Chen*[¶]

*Institute of Pathology, Case Western Reserve University and National Prion Disease Pathology Surveillance Center, 2085 Adelbert Road, Cleveland, OH 44106; [†]Ortho-Clinical Diagnostics, 1001 U.S. Highway 202, Raritan, NJ 08869; and [§]Department of Molecular and Cell Biology, University of Texas at Dallas, P.O. Box 830688, Richardson, TX 75083

Prion diseases, a group of fatal neurodegenerative disorders, are characterized by the presence of the abnormal scrapie isoform of prion protein (PrP^{Sc}) in affected brains. A conformational change is believed to convert the normal cellular prion protein into PrP^{Sc}. Detection of PrP^{Sc} for diagnosis and prophylaxis is impaired because available Abs recognizing epitopes on PrP fail to distinguish between PrP^{Sc} and normal cellular prion protein. Here, we report that an anti-DNA Ab, OCD4, as well as gene 5 protein, a well established DNA-binding protein, capture PrP from brains affected by prion diseases in both humans and animals but not from unaffected controls. OCD4 appears to immunoreact with DNA (or a DNA-associated molecule) that forms a conformation-dependent complex with PrP in prion diseases. Whereas PrP immunocaptured by OCD4 is largely protease-resistant, a fraction of it remains protease-sensitive. Moreover, OCD4 detects disease-associated PrP >10 times more efficiently than a widely used Ab to PrP. Our finding that anti-DNA Abs and gene 5 protein specifically target disease-associated DNA–PrP complexes in a wide variety of species and disease phenotypes opens new avenues in the study and diagnosis of prion diseases.

H uman prion diseases include sporadic and familial forms (1), such as Creutzfeldt–Jakob disease (CJD) and Gerstmann–Sträussler–Scheinker disease (GSS), as well as acquired forms such as variant CJD (vCJD) transmitted through the consumption of contaminated beef (2, 3). Scrapie in sheep and goats, bovine spongiform encephalopathy (BSE) in cows, and chronic wasting disease (CWD) in deer and elk are the most common prion diseases in animals. According to the prevailing prion hypothesis (4), all forms of prion diseases share a pathogenic mechanism whereby the host-encoded normal cellular prion protein (PrP^C) is converted into the abnormal scrapie isoform of prion protein (PrP^{Sc}) isoform that is insoluble, pathogenic, and infectious. The PrP^C to PrP^{Sc} conversion is believed to take place posttranslationally and to involve an α-helix to β-sheet structural transition (5–8). The presence and location of the β-sheet structure is thought to make PrP^{Sc} resistant to proteases and to result in a variety of PrP^{Sc} conformers known as prion strains (9). How this conversion takes place, the precise physicochemical characteristics of the converted PrP^{Sc} conformer, and whether additional molecules, including nucleic acid (10, 11), are also components of the infectious agent are issues that have never been fully clarified. The possibility of the spread of prion diseases in animals and from animals to humans (12, 13) has prompted the generation of many Abs against PrP sequences as possible diagnostic reagents. However, most of them recognize both the PrP^C and PrP^{Sc} isoforms. A previous report of an Ab immunoreacting specifically with PrP^{Sc} has not been confirmed in subsequent studies (14).

Recent evidence suggests that PrP may form a macromolecular complex with nucleic acid (15). To explore whether nucleic acid represents a possible target for PrP^{Sc} detection, we screened anti-DNA Abs for their ability to capture PrP^{Sc} from homogenates of diseased brains. Surprisingly, several Abs to DNA readily identified PrP in the immunocapture assay. Moreover, like anti-DNA Abs, Ff gene 5 protein (g5p), a single-stranded DNA-binding protein is also capable of capturing PrP^{Sc}. OCD4, a mAb raised against a nuclear DNA preparation from human lymphoma cells, was selected for detailed analyses.

Materials and Methods

Reagents and Anti-PrP Abs. Magnetic beads (M-280 tosyl-activated Dynabeads) were from Dynal (Oslo). Salmon testes single-stranded DNA and proteinase K (PK) were purchased from Sigma. Nuclease (benzonase) was from Roche Diagnostics (Indianapolis). Mouse mAb 6H4 from Prionics (Zurich) was used to recognize the sequence of human PrP residues 144–152 (16). Mouse mAb 3F4 from Signet Laboratories (Dedham, MA) was used to recognize an epitope within human PrP residues 109–112 (17). The rabbit anti-C antiserum immunoreacted with human PrP residues 220–231 (18). Horseradish peroxidase-conjugated Ab was purchased from Amersham Biosciences (Piscataway, NJ).

Brain Tissues. Human brain tissues were obtained at autopsy from patients with or without prion diseases and were kept frozen at $-80°C$. The diagnosis of various disease phenotypes of sporadic CJD (sCJD), familial CJD (fCJD), vCJD, and GSS was confirmed by standard criteria, including histological examination, immunohistochemistry, immunoblotting, and DNA typing. Animal brain tissues with or without prion disease were confirmed by immunohistochemistry and immunoblotting as well.

Production of Anti-DNA Ab. Nuclear DNA extracted (19) from Raji Burkitts lymphoma cells was used as an immunogen to generate OCD4. The production of mAb was carried out according to a standard protocol (20). Screening of mAb by enzyme-linked immunoabsorbent assay was performed by using 96-well plates coated with calf thymus DNA (Sigma).

Preparation of g5p. The g5p (PDB ID code 1VQB) was isolated from *Escherichia coli* transformed with an Ff gene 5-containing plasmid and purified by using DNA cellulose affinity plus Sephadex G75 sizing columns as described (21, 22). The purity of g5p was >99% as determined by quantitation of Coomassie blue-stained bands on SDS-polyacrylamide gels.

Immunocapture Assay. OCD4 (100 μg of purified IgG) was conjugated to 7×10^8 tosyl-activated superparamagnetic beads (M-280 Dynabeads, Dynal) in 1 ml of PBS at 37°C for 20 h. The OCD4-conjugated beads were incubated with 0.1% BSA in PBS

---

to block nonspecific binding. The prepared OCD4 beads were stable for at least 3 months at 4°C. Brain homogenate (BH) (10%, wt/vol) was prepared at 4°C in lysis buffer (100 mM NaCl/10 mM EDTA/0.5% Nonidet P-40/0.5% sodium deoxycholate/10 mM Tris·HCl, pH 7.5) containing a mixture of protease inhibitors (Roche Applied Science), followed by centrifugation at 3,000 × g for 10 min at 4°C to remove debris. Immunoprecipitation (IP) was then performed as described (23) by using the clarified homogenate (10 μl for human and 2 μl for animal specimens) and OCD4-conjugated beads (10 μg of mAb/6 × 10⁷ beads) in 1 ml of lysis buffer. After incubation with constant mixing for 3 h at room temperature, OCD4 beads were attracted to the side wall of the plastic tubes by external magnetic force, allowing easy removal of all unbound materials in the solution. After three washes in wash buffer (2% Tween 20 and 2% Nonidet P-40 in PBS, pH 7.5), OCD4 beads were collected and were heated at 95°C for 5 min in SDS sample buffer (3% SDS/2 mM EDTA/10% glycerol/50 mM Tris·HCl, pH 6.8).

Immunoblotting. Proteins were separated by SDS/PAGE (15% Tris-glycine precast gel, Bio-Rad), electrotransferred onto a polyvinylidene difluoride membrane. PrP was detected by immunoblotting using the following anti-PrP Abs: 3F4 mAb used at 1:50,000, 6H4 mAb used at 1:5,000, and anti-C antiserum used at 1:3,000. For DNA dot blot analysis, purified salmon sperm DNA (Sigma) was dissolved in distilled and deionized H_2O (Millipore) and a 1-μl aliquot was dotted onto a nitrocellulose membrane. The blot was dried at 80°C for 1 h, blocked with 5% milk that was pretreated with nuclease (benzonase; 20 units/ml for 1 h at room temperature), followed by incubation with horseradish peroxidase-conjugated OCD4 (1:2,000 dilution) at room temperature for 1 h. Immunoreactivity was visualized on Kodak x-ray film by enhanced chemiluminescence with the ECL plus kit (Amersham Biosciences).

PK Digestion. Samples were incubated in lysis buffer with PK at 50 μg/ml at 37°C for 1 h. The digestion was terminated by addition of 5 mM phenylmethylsulfonyl fluoride. The digested samples were mixed with an equal volume of 2× SDS sample buffer before SDS/PAGE and immunoblotting with an anti-PrP Ab.

Conformation-Dependent Immunoassay. The conformation-dependent stability of PrPSc was analyzed by using a modified procedure based on published methods (24, 25). BH (10%, wt/vol) from a CJD subject was treated with 0–3 M guanidine hydrochloride (GdnHCl) in lysis buffer at room temperature for 1 h. GdnHCl was subsequently removed by precipitation with 5-fold volumes of prechilled methanol at −20°C for 2 h, followed by centrifugation at 16,000 × g for 20 min at 4°C. The pellets were resuspended in lysis buffer. PrPSc in the GdnHCl-treated samples were evaluated either by PK digestion (50 μg/ml PK for 1 h at 37°C) or by immunocapture with OCD4, followed by immunoblotting with 3F4 as described above.

Results

An Anti-DNA Ab Specifically Captures PrPSc but Not PrPC. We performed the immunocapture assay of PrP by using the anti-DNA Ab-conjugated magnetic beads, followed by immunoblotting with an anti-PrP Ab. Immunocapture by the mAb to DNA OCD4 yielded abundant PrP from BH of CJD subjects, whereas no PrP was recovered from control brains free of neurological disease, as well as brains with other neurodegenerative diseases, such as Alzheimer's disease (Fig. 1A and data not shown). None of the other mAbs recognizing PrP sequences demonstrated such high specificity. Under the same experimental conditions, two of these Abs to PrP widely used in current research on prion diseases, mAbs 3F4 (17) and 6H4 (16), immunocaptured PrP

Fig. 1. Immunocapture of disease-associated PrP by anti-DNA mAb OCD4. (A) PrP captured from BHs by various mAbs. Ten microliters of 10% (wt/vol) BH from a subject with sporadic CJD or a non-CJD control was incubated in 1 ml of lysis buffer for 3 h at room temperature with OCD4, 3F4, and 6H4 that were conjugated to magnetic beads (23). After washing with a solution of 2% Tween 20 and 2% Nonidet P-40 in PBS, the samples recovered by the Ab-conjugated beads were subjected to SDS/PAGE. PrP was detected by immunoblotting with 3F4. (B) Immunocapture of PrP from a subject with sCJD by antitubulin Ab and OCD4. Experimental procedures were the same as those described for A. Molecular mass markers (in kDa) are indicated on the left.

from both diseased and normal brains. The mAbs 3F4 and 6H4 actually showed higher affinity for PrPC than for the PrP associated with CJD brains (Fig. 1A). To exclude the possibility that binding of PrPSc to OCD4-conjugated beads is nonspecific, we conjugated an Ab against tubulin to the beads and assayed for PrP in CJD BH after immunocapture. No PrP was captured by this irrelevant Ab, whereas abundant amounts of PrP were recovered by OCD4 from the same preparation (Fig. 1B).

OCD4 Immunoreacts with DNA, and OCD4 Detection of PrP Is Competed by Input DNA. To determine whether DNA is indeed the antigen recognized by OCD4, we performed the DNA dot blot assay. We found that OCD4 immunoreacts with purified DNA preparations and that the reaction is sensitive to nuclease (Fig. 2A). We also preabsorbed the OCD4-conjugated beads with purified DNA before performing the immunocapture assay. Alternatively, we treated the BHs with nuclease (benzonase) followed by immunocapture with OCD4. No PrP was immunocaptured by OCD4 in the presence of the added DNA. However, pretreatment of the homogenate with nuclease had no effect on PrP immunocapture by OCD4, even although, in a control experiment, the amount of nuclease used was sufficient to digest the DNA added to the preparation (Fig. 2 B and C). Taken together, these findings argue that the OCD4 antigen is DNA, or a DNA-related molecule that is part of a molecular complex with disease-associated PrPSc. The ineffectiveness of the nuclease digestion suggests that the DNA present in the DNA–PrPSc complex may be protected from, or inaccessible to, nuclease digestion while maintaining the capacity to bind OCD4. Nucleic acid specifically isolated from CJD brain has been reported to resist nuclease treatment (26). Furthermore, we also observed that disease-associated PrPSc could be specifically isolated with

NEUROSCIENCE

Fig. 2. Immunoreactivity of OCD4 toward DNA and effect of DNA and nuclease on PrP capture by OCD4. (*A*) Dot blot of DNA probed with OCD4. (*Left*) Dot blot containing indicated amounts of purified salmon DNA was incubated with horseradish peroxidase-conjugated OCD4. (*Right*) Salmon sperm DNA was treated with or without nuclease (Nucl., benzonase) at 20 units/ml at 37°C for 1 h before dot blot with horseradish peroxidase-conjugated OCD4. Immunoreactivity was visualized by enhanced chemiluminescence. (*B*) Immunocapture of PrP by OCD4 after incubation with nuclease and salmon DNA. Scrapie-infected hamster BH (2 μl each) was either untreated (control) or treated with benzonase (nuclease) at 100 units/ml, followed by incubation with OCD4-conjugated beads. In a separate sample, purified salmon DNA (5 μg/ml) was preincubated with the OCD4-conjugated beads at 37°C for 1 h before the immunocapture assay (DNA). PrP was detected by immunoblotting with 3F4. Molecular mass is indicated on the left (in kDa). (*C*) Enzymatic digestion of DNA by nuclease. Salmon DNA (5 μg/ml) was treated with benzonase at 20 units/ml or 2 units/ml at 37°C for 1 h, or was left untreated. The samples were subjected to 1.0% agarose gel electrophoresis, with a 1-kb DNA ladder (Sigma) run in parallel as DNA size standard.

Fig. 3. Capture of PrP from sCJD, vCJD, and normal control brains by g5p. (*A*) BH from subjects affected by vCJD and sCJD and from a control subject was incubated with g5p- or OCD4-conjugated beads, followed by immunoblotting with 3F4. (*B*) The g5p- or OCD4-conjugated beads were preincubated with indicated amounts of salmon DNA, followed by incubation with BH of sCJD and immunoblotting with 3F4.

other mAbs raised with different DNA preparations (data not shown). Alternatively, OCD4 and other mAbs to DNA as well, might recognize a conformation shared by PrP^{Sc} and DNA.

The DNA-Binding Protein g5p also Captures PrP^{Sc} in a DNA-Dependent Manner. The DNA-binding protein g5p, encoded by the filamentous bacteriophage Ff and purified from *E. coli* (21, 22), was conjugated to magnetic beads. The g5p-conjugated beads were then incubated with BHs from vCJD, sCJD, or normal controls. Like OCD4, g5p precipitated PrP from vCJD and sCJD brains, but not from normal control brains (Fig. 3*A*). Moreover, the amount of the PrP captured by both g5p and OCD4 decreased in a concentration-dependent manner after the addition of DNA (Fig. 3*B*), further arguing that the capture of PrP by OCD4 and g5p is mediated by, or can be competed with, nucleic acid.

OCD4-Captured PrP^{Sc} Is PK-Resistant, and OCD4 Detects PrP^{Sc} of Different Prion Strains in Both Humans and Animals. A major portion of the PrP captured by OCD4 is resistant to PK digestion, which is the biochemical hallmark of PrP^{Sc} (Fig. 4*A*). Furthermore, whereas the currently available mAbs to PrP are species-sensitive because their specificity is derived from a particular PrP sequence (14, 16, 27), OCD4 captured all disease-associated PrP^{Sc} of different prion strains, which were obtained from various forms of human prion diseases, including sporadic and fCJD, GSS, and vCJD, as well as naturally occurring and experimen-

tally transmitted animal diseases (Fig. 4). These findings further argue that under nondenaturing conditions, OCD4 captures disease-associated PrP^{Sc} but not PrP^C. Furthermore, OCD4

Fig. 4. OCD4 captures disease-associated PrP^{Sc} from various prion-infected human and animal brains. (*A*) Immunocapture of PrP by OCD4 from various human prion diseases. BH (10 μl each) from subjects affected by sCJD associated with PrP^{Sc} type 1 or PrP^{Sc} type 2 (28, 29), fCJD linked to the E200K mutation (fCJD), and vCJD, as well as from a non-CJD control, was incubated with OCD4-conjugated beads. The bound materials were either untreated (PK−) or treated with PK (PK+) at 50 μg/ml at 37°C for 1 h. PrP was detected by immunoblotting with 3F4. (*B*) Immunocapture of PrP by OCD4 from various animal species. BH (2 μl each) from normal animals and those affected by BSE (cattle), scrapie (sheep), and CWD (deer), as well as experimental scrapie adapted in hamster (263 K prion strain) and mouse (ME7 prion strain), was subjected to immunocapture by OCD4 as described in *A*. Captured PrP was detected by immunoblotting with 6H4.

Fig. 5. Immunocapture of various PK-resistant PrP fragments by OCD4. BH from subjects affected by sCJD associated with codon 129 MM and type 2 PrP^{Sc} (sCJD MM2; *A*), fCJD with the E200K mutation (fCJD E200K; *B*), and GSS with the P102L mutation (GSS P102L; *C*) was treated with or without PK at 50 μg/ml at 37°C for 1 h. PrP was captured by the OCD4-conjugated beads and was then detected by immunoblotting with either 3F4 recognizing PrP residues 109–112 (*A* and *C*) or the anti-C Ab against human PrP residues 220–231 (*B*). Three groups of PK-resistant PrP fragments were efficiently captured by OCD4 (with their position on the blots indicated), including the ≈19-kDa PrP core fragment spanning residues 97–103 to 231 (bracket; ref. 28), the internal 7- to 8-kDa fragment spanning residues 74–90 to 146–153 (dagger; refs. 30–32), and the C-terminal 12- to 13-kDa fragment spanning residues 154–162 to 231 (asterisk; ref. 33).

must immunoreact with an antigen that is bound to, but distinct from, PrP, because the OCD4 capture of PrP is independent of PrP amino acid sequence.

OCD4 Captures all PK-Resistant PrP Fragments Associated with Various Human Prion Diseases.

To gain insight into the PrP bound to the putative DNA-containing complex, we took advantage of the different size of the PK-resistant PrP^{Sc} core fragments present in various prion diseases. Immunocapture of PrP by OCD4 was not affected by pretreatment of homogenates from diseased brains with PK (Fig. 5). Furthermore, all major PK-resistant fragments of PrP^{Sc} were recovered, including the 21- and 19-kDa core fragment in CJD (PrP^{Sc} type 1 and 2; Fig. 5*A*) spanning residues 82–97 to 231 (28, 29), which accounts for nearly two-thirds of the 23–231 PrP molecule; an internal 7- to 8-kDa fragment in GSS (Fig. 5*C*), including residues 74–90 to 146–153 (30–32), and the C-terminal 12- to 13-kDa fragment in CJD (Fig. 5*B*), extending from residues 154–162 to 231 (33). The cocapture by OCD4 of all major PrP^{Sc} fragments generated by PK treatment regardless of size argues that most (if not all) of the PK-resistant region of PrP^{Sc} is stably bound to the DNA-containing complex and remains with the complex after PK treatment. It also further supports the contention that OCD4 is unlikely to react directly with PrP in the complex because the 7- to 8-kDa internal fragment and the 12- to 13-kDa C-terminal fragment share no consensus in sequence, yet they are both efficiently captured by OCD4.

The Immunocapture of PrP^{Sc} by OCD4 Is Conformation-Dependent.

Because the protease resistance and other physicochemical features of PrP^{Sc} are thought to depend on protein conformation, distinct conformers of PrP^{Sc} have been characterized based on the extent of the loss in protease resistance as a function of increased exposure to denaturants (24). We applied such a conformation-dependent immunoassay to compare the conformational characteristics of the PrP captured by OCD4 with those of native PrP^{Sc} present in the homogenate from the same CJD brain. The decrease of PK resistance with rising concentrations of GdnHCl took place at a comparable rate for native PrP^{Sc}- and OCD4-captured PrP (Fig. 6 *A* and *B*), suggesting that PK-resistant forms of native PrP^{Sc}- and OCD4-captured PrP have comparable conformational properties. We then examined the

Fig. 6. Conformation-dependent immunocapture of disease-associated PrP by OCD4. (*A*) PK resistance of PrP^{Sc} as a function of GdnHCl concentrations. BH from CJD was treated with various concentrations of GdnHCl. The GdnHCl-treated samples were digested with 50 μg/ml PK for 1 h at 37°C (PK+) followed by immunoblotting with 3F4. (*B*) PK resistance of PrP captured by OCD4 as a function of GdnHCl concentrations. The GdnHCl-treated BH of CJD was subjected to IP with OCD4, followed by digestion with PK (IP/+PK). PrP was then detected by immunoblotting with 3F4. (*C*) Capture of PrP by OCD4 as a function of GdnHCl concentrations. The GdnHC-treated BH of CJD was subjected to IP with OCD4 without the PK treatment (IP/−PK). PrP was detected by immunoblotting with 3F4. (*D*) Comparison of GdnHCl-dependent loss of PrP in BH of CJD after PK digestion (●), IP with OCD4 followed by PK digestion (○), and IP with OCD4 without PK digestion (■). Intensity of PrP bands on immunoblots was quantified by densitometry, and the ratio of PrP in the GdnHCl-treated and untreated samples was plotted as a function of GdnHCl concentrations. Similar results were obtained in two additional experiments.

affinity of OCD4 for PrP as a function of GdnHCl treatment. Decreasing amounts of PrP were recovered by immunocapture with OCD4 after protein denaturation by increasing concentrations of GdnHCl (Fig. 6*C*), arguing that the affinity of OCD4 for PrP is also conformation-dependent. Whether and how the conformation of the complex and that of PrP are related remain to be clarified. The report that recombinant PrP carrying a largely α-helical conformation was converted to an isoform rich in β-structure after exposure to a DNA sequence is pertinent to these questions (15). Furthermore, by comparing *B* and *C* of Fig. 6, it is obvious that the total PrP captured by OCD4 exceeds that in the PK-resistant fraction. Densitometry showed that >20% of PrP was still detectable after treatment with 2.4 M GdnHCl that renders virtually all PrP^{Sc} sensitive to PK (Fig. 6*C*), suggesting that at least 20% of PrP recovered by OCD4 is PK-sensitive. Therefore, PrP captured by OCD4 comprises both PK-resistant and PK-sensitive PrP species as has been reported for PrP^{Sc} after

A

29–

21–

| BH (µl) | 0.5 | 1.0 | 1.5 | 2.0 | | 0.5 | 1.0 | 1.5 | 2.0 |

Diluted in 1 ml PBS
and IP with 3F4
Prior to SDS-PAGE

Diluted in 1 ml PBS
and IP with OCD4
prior to SDS-PAGE

B

Intensity of PrP precipitated (arbitrary unit, X1,000)

☐ 3F4
☐ OCD4

| Input BH (µl) | 0.5 | 1.0 | 1.5 | 2.0 |
| Dilution (folds) | 1:2,000 | 1:1,000 | 1:667 | 1:500 |

Fig. 7. Recovery of PK-resistant PrP from diluted CJD BH by OCD4 and 3F4. (A) BH (10%, wt/vol) from a CJD subject was treated with 50 µg/ml PK for 1 h at 37°C. Four aliquots of PK-treated BH ranging from 0.5 to 2.0 µl were diluted into 1 ml of PBS representing a dilution of 2,000- to 500-fold. Samples were then subjected to IP with either 3F4 or OCD4, followed by immunoblotting with 3F4. (B) Comparison of PrP recovered by IP with 3F4 and OCD4. Signal intensity (arbitrary unit) of PrP on immunoblots was quantified by densitometry. Compared with 3F4, OCD4 recovered significantly higher amounts (11.7 ± 5.2 times more) of PK-resistant PrP ($P = 0.004$; Welch's t test).

a conformation-dependent assay and other analyses (25, 34). Taken together, the similarity in gel migration pattern and in the conformation dependence of the PK resistance, as well as the presence of both PK-sensitive and -resistant components, argue that PrP captured by OCD4 and native PrP^{Sc} are the same.

OCD4 Possesses High Affinity to PrP^{Sc}. The specificity of OCD4 to disease-associated PrP makes it potentially a suitable reagent to detect small concentrations of infectious PrP that may be present in body fluids and peripheral organs. In a crude affinity assay, small amounts of PK-treated homogenate from a CJD brain were diluted in large volume and PrP was then captured with either OCD4 or the commercially available mAb 3F4 (Fig. 7A). In four dilutions between 500- and 2,000-fold, OCD4, on average, detected the PK-resistant PrP >10-fold more efficiently than did 3F4 (11.7- ± 5.2-fold more; $P = 0.004$, Welch's t test; Fig. 7B). Because OCD4 was also observed to have a better capture efficiency for PrP^{Sc} than another anti-PrP Ab, 6H4 (Fig. 1), the above findings suggest that OCD4 is indeed a high-affinity PrP^{Sc} capture reagent.

Discussion

In this study we observed, for the first time, to our knowledge, that the mAb to DNA OCD4 and the single-stranded DNA-binding protein g5p can capture PrP^{Sc} but not PrP^{C}. These findings suggest that the capture of PrP^{Sc} by OCD4 and g5p depends on nucleic acid and that PrP^{Sc} forms a complex with nucleic acid. The sequence of the nucleic acid associated with PrP^{Sc}, and whether the PrP^{Sc}–nucleic acid complexes are present *in vivo* as previously suggested (26, 35–38), or form only in the homogenized tissue, remain to be determined.

Several recent studies (39, 40) have reported the generation of conformation-dependent mAbs that react with disease-related amyloid proteins. The Abs described by O'Nuallain and Wetzel (39) react with a variety of amyloid fibrils made of different proteins but not with their respective precursor proteins. Kayed et al. (40) also observed a polyclonal Ab that recognizes soluble amyloid oligomers of the amyloid β peptides associated with Alzheimer's disease (but not amyloid fibrils) as well as with soluble oligomeric aggregates formed by other disease-related proteins (40). It has been proposed that these Abs recognize a conformation shared by amyloid fibrils or soluble amyloid oligomers regardless of their primary structure (39, 40). These reports raise an alternative possibility that OCD4 is also a conformational Ab that recognizes a conformation shared by PrP^{Sc} and DNA. Both DNA and amyloids contain repeat structures that might result in a conformation that binds OCD4 despite the different nature of the core molecules (39). Future tests are warranted to resolve these possibilities. There is also a recent paper from Paramithiotis et al. (41) that polyclonal Abs and mAbs directed against the PrP repeat motif Tyr-Tyr-Arg specifically react with PrP^{Sc} apparently in a non-DNA-dependent fashion.

The mAb OCD4 is remarkable in several respects. First, it captures the abnormal PrP associated with prion diseases with a high level of specificity and affinity while not recognizing PrP^{C} at all. Second, it detects both protease-sensitive and protease-resistant species of prion disease-associated PrP. Third, it suggests that both species of abnormal PrP form a complex that includes DNA or DNA-related molecules. Fourth, because several other Abs to DNA preparations also capture the disease-associated PrP and they are easy to produce, OCD4 is likely to be the first of many novel prion-specific reagents. Abs to DNA may help develop new strategies for the study, detection, and treatment of prion diseases.

1. Gambetti, P., Kong, Q., Zou, W. Q., Parchi, P. & Chen, S. G. (2003) *Br. Med. Bull.* **66**, 213–239.
2. Will, R. G., Ironside, J. W., Zeidler, M., Cousens, S. N., Estibeiro, K., Alperovitch, A., Poser, S., Pocchiari, M., Hofman, A. & Smith, P. G. (1996) *Lancet* **347**, 921–925.
3. Bruce, M. E., Will, R. G., Ironside, J. W., McConnell, I., Drummond, D., Suttie, A., McCardle, L., Chree, A., Hope, J., Birkett, C., *et al.* (1997) *Nature* **389**, 498–501.
4. Prusiner, S. B. (1998) *Proc. Natl. Acad. Sci. USA* **95**, 13363–13383.
5. Caughey, B. W., Dong, A., Bhat, K. S., Ernst, D., Hayes, S. F. & Caughey, W. S. (1991) *Biochemistry* **30**, 7672–7682.
6. Pan, K. M., Baldwin, M., Nguyen, J., Gasset, M., Serban, A., Groth, D., Mehlhorn, I., Huang, Z., Fletterick, R. J., Cohen, F. E., *et al.* (1993) *Proc. Natl. Acad. Sci. USA* **90**, 10962–10966.
7. Safar, J., Roller, P. P., Gajdusek, D. C. & Gibbs, C. J., Jr. (1993) *J. Biol. Chem.* **268**, 20276–20284.
8. Cohen, F. E., Pan, K. M., Huang, Z., Baldwin, M., Fletterick, R. J & Prusiner, S. B. (1994) *Science* **264**, 530–531.
9. Telling, G. C., Telling, G. C., Parchi, P., DeArmond, S. J., Cortelli, P., Montagna, P., Gabizon, R., Mastrianni, J., Lugaresi, E., Gambetti, P., *et al.* (1996) *Science* **274**, 2079–2082.

10. Gajdusek, D. C. (1977) *Science* **197,** 943–960.
11. Bruce, M. E. & Dickinson, A. G. (1987) *J. Gen. Virol.* **68,** 79–89.
12. Prusiner, S. B. (1997) *Science* **278,** 245–251.
13. Momcilovic, D. & Rasooly, A. (2000) *J. Food Prot.* **63,** 1602–1609.
14. Korth, C., Stierli, B., Streit, P., Moser, M., Schaller, O., Fischer, R., Schulz-Schaeffer, W., Kretzschmar, H., Raeber, A., Braun, U., *et al.* (1997) *Nature* **390,** 74–77.
15. Cordeiro, Y., Machado, F., Juliano, L., Juliano, M. A., Brentani, R. R., Foguel, D. & Silva, J. L. (2001) *J. Biol. Chem.* **276,** 49400–49409.
16. Korth, C., Streit, P. & Oesch, B. (1999) *Methods Enzymol.* **309,** 106–122.
17. Kascsak, R. J., Rubenstein, R., Merz, P. A., Tonna-DeMasi, M., Fersko, R., Carp, R. I., Wisniewski, H. M. & Diringer, H. (1987) *J. Virol.* **61,** 3688–3693.
18. Chen, S. G., Teplow, D. B., Parchi, P., Teller, J. K., Gambetti, P. & Autilio-Gambetti, L. (1995) *J. Biol. Chem.* **270,** 19173–19180.
19. Sambrook, J., Fritsch, E. F. & Maniatis, T. (1989) in *Molecular Cloning: A Laboratory Manual*, eds. Sambrook, J., Fritsch, E. F. & Maniatis, T. (Cold Spring Harbor Lab. Press, Plainview, NY), pp. 9.14–9.23.
20. Yokoyama, W. M. (2001) in *Current Protocols in Cell Biology*, eds. Bonifacino, J. S., Dasso, M., Harford, J. B., Lippincott-Schwartz, J. & Yamada, K. M. (Wiley, New York), pp. 16.1.1–16.1.17.
21. Thompson, T. M., Mark, B. L., Gray, C. W., Terwilliger, T. C., Sreerama, N., Woody, R. W. & Gray, D. M. (1998) *Biochemistry* **37,** 7463–7477.
22. Mou, T.-C., Gray, C. W. & Gray, D. M. (1999) *Biophys. J.* **76,** 1537–1551.
23. Zou, W. Q. & Cashman, N. R. (2002) *J. Biol. Chem.* **277,** 43942–43947.
24. Peretz, D., Scott, M. R., Groth, D., Williamson, R. A., Burton, D. R., Cohen, F. E. & Prusiner, S. B. (2001) *Protein Sci.* **10,** 854–863.
25. Safar, J., Wille, H., Itri, V., Groth, D., Serban, H., Torchia, M., Cohen, F. E. & Prusiner, S. B. (1998) *Nat. Med.* **4,** 1157–1165.
26. Sklaviadis, T., Akowitz, A., Manuelidis, E. E. & Manuelidis, L. (1990) *Arch. Virol.* **112,** 215–228.
27. Peretz, D., Williamson, R. A., Matsunaga, Y., Serban, H., Pinilla, C., Bastidas, R. B., Rozenshteyn, R., James, T. L., Houghten, R. A., Cohen, F. E., *et al.* (1997) *J. Mol. Biol.* **273,** 614–622.
28. Parchi, P., Zou, W., Wang, W., Brown, P., Capellari, S., Ghetti, B., Kopp, N., Schulz-Schaeffer, W. J., Kretzschmar, H. A., Head, M. W., *et al.* (2000) *Proc. Natl. Acad. Sci. USA* **97,** 10168–10172.
29. Zou, W., Colucci, M., Gambetti, P. & Chen, S. G. (2002) in *Methods in Molecular Biology-Neurogenetics: Methods and Protocols*, ed. Potter, N. T. (Humana, Totowa, NJ), pp. 305–314.
30. Tagliavini, F., Prelli, F., Ghiso, J., Bugiani, O., Serban, D., Prusiner, S. B., Farlow, M. R., Ghetti, B. & Frangione, B. (1991) *EMBO. J.* **10,** 513–519.
31. Tagliavini, F., Prelli, F., Porro, M., Rossi, G., Giaccone, G., Farlow, M. R., Dlouhy, S. R., Ghetti, B., Bugiani, O. & Frangione, B. (1994) *Cell* **79,** 695–703.
32. Parchi, P., Chen, S. G., Brown, P., Zou, W., Capellari, S., Budka, H., Hainfellner, J., Reyes, P. F., Golden, G. T., Hauw, J. J., *et al.* (1998) *Proc. Natl. Acad. Sci. USA* **95,** 8322–8327.
33. Zou, W. Q., Capellari, S., Parchi, P., Sy, M. S., Gambetti, P. & Chen, S. G. (2003) *J. Biol. Chem.* **278,** 40429–40436.
34. Caughey, B., Raymond, G. J., Callahan, M. A., Wong, C., Baron, G. S. & Xiong, L. W. (2001) *Adv. Protein Chem.* **57,** 139–169.
35. Marsh, R. F., Malone, T. G., Semancik, J. S., Lancaster, W. D. & Hanson, R. P. (1978) *Nature* **275,** 146–147.
36. Aiken, J. M., Williamson, J. L., Borchardt, L. M. & Marsh, R. F. (1990) *J. Virol.* **64,** 3265–3268.
37. Akowitz, A., Sklaviadis, T. & Manuelidis, L. (1994) *Nucleic Acids Res.* **22,** 1101–1107.
38. Narang, H. K., Asher, D. M. & Gajdusek, D. C. (1988) *Proc. Natl. Acad. Sci. USA* **85,** 3575–3579.
39. O'Nuallain, B. & Wetzel, R. (2002) *Proc. Natl. Acad. Sci. USA* **99,** 1485–1490.
40. Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W. & Glabe, C. G. (2003) *Science* **300,** 486–489.
41. Paramithiotis, E., Pinard, M., Lawton, T., LaBoissiere, S., Leathers, V. L., Zou, W. Q., Estey, L. A., Lamontagne, J., Lehto, M. T., Kondejewski, L. H., *et al.* (2003) *Nat. Med.* **9,** 893–899.

NEUROSCIENCE